This company listing is no longer active
LumiraDx Past Earnings Performance
Past criteria checks 0/6
LumiraDx's earnings have been declining at an average annual rate of -212%, while the Medical Equipment industry saw earnings growing at 11.4% annually. Revenues have been declining at an average rate of 68.3% per year.
Key information
-212.0%
Earnings growth rate
-122.2%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | -68.3% |
Return on equity | n/a |
Net Margin | -267.2% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Market Cool On LumiraDx Limited's (NASDAQ:LMDX) Revenues Pushing Shares 27% Lower
Dec 20LumiraDx Limited's (NASDAQ:LMDX) Revenues Are Not Doing Enough For Some Investors
Apr 17What You Need To Know About The LumiraDx Limited (NASDAQ:LMDX) Analyst Downgrade Today
Nov 16Need To Know: The Consensus Just Cut Its LumiraDx Limited (NASDAQ:LMDX) Estimates For 2022
Aug 20LumiraDx GAAP EPS of -$0.58, revenue of $44.7M
Aug 18Bill & Melinda Gates Foundation discloses 7.4% passive stake in LumiraDx
Jul 15Revenue & Expenses Breakdown
How LumiraDx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 127 | -338 | 114 | 87 |
31 Mar 23 | 150 | -436 | 129 | 118 |
31 Dec 22 | 254 | -448 | 143 | 140 |
30 Sep 22 | 332 | -384 | 151 | 154 |
30 Jun 22 | 398 | -108 | 144 | 158 |
31 Mar 22 | 441 | 24 | 133 | 145 |
31 Dec 21 | 421 | -101 | 131 | 130 |
30 Sep 21 | 415 | -183 | 109 | 124 |
30 Jun 21 | 320 | -331 | 93 | 117 |
31 Mar 21 | 240 | -368 | 75 | 108 |
31 Dec 20 | 139 | -241 | 46 | 108 |
30 Sep 20 | 33 | -201 | 41 | 103 |
30 Jun 20 | 25 | -171 | 39 | 98 |
31 Mar 20 | 24 | -152 | 38 | 92 |
31 Dec 19 | 23 | -133 | 37 | 87 |
31 Dec 18 | 25 | -115 | 36 | 67 |
Quality Earnings: LMDX.F is currently unprofitable.
Growing Profit Margin: LMDX.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LMDX.F's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LMDX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LMDX.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.5%).
Return on Equity
High ROE: LMDX.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/10/28 10:41 |
End of Day Share Price | 2024/10/28 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LumiraDx Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mark Massaro | BTIG |
Vijay Kumar | Evercore ISI |
Matthew Sykes | Goldman Sachs |